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Background:  Cardiac  device-related  endocarditis  (CDE)  is  a major  complication  of the  implantation  of a
pacemaker  and  deﬁbrillator.  The  experience  in  a single  high-volume  tertiary  center  is  reported.
Methods:  Thirty  one  years  (1980–2011)  of  cases  of  CDE  were  analyzed  retrospectively  and  compared
to  overall  insertion  data; the  clinical  course  and  management  strategies  of  these  patients  have  been
reviewed.
Results:  A  total  of 23  cases  (16  male,  median  age  72  years)  were  identiﬁed,  20 of  these  cases  were  deter-
mined  at  our  institution  where  5287  procedures  were  performed  (endocarditis  rate  0.38%).  Thirteen
patients  were  determined  to  have  a cardiac  device  pocket  infection.  Infection  in  7 cases  (30%)  was  caused
by lead(s).  However,  in  16  cases  (70%)  both  leads  and  the  pocket  of  devices  were  the  reason  of infection.
Median  time  was  13.5  months  for presentation.  Patients  who  had  undergone  the  last  procedure  within
6 months  were  admitted  earlier  than  those  with  longer  post  procedure  time  (p  < 0.05).  Transesophageal
echocardiography  demonstrated  lead  vegetations  in 13  of  the  16 cases  (81%).  Organisms  were  identiﬁed
in  18  cases  (78%)—78%  Staphylococci  (56%  Staphylococcus  aureus).  Leads  of the  device  were  removed
in  17  cases  (74%);  seven  cases  by percutaneous  simple  traction  and  10  cases  by  sternotomy.  Six major
complications  attributable  to  device-related  endocarditis  were  observed:  four deaths  (mortality  17.4%);
one splenic  abscess  requiring  splenectomy;  and  one  septic  pulmonary  embolism;  median  follow-up  49
months.
Conclusion:  A  CDE  endocarditis  rate  of  0.38%  was  demonstrated.  It remains  a rare  but potentially  lethal
plan
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Implantation of electrophysiological cardiac devices such
s pacemakers and implantable cardioverter deﬁbrillators has
ecome a widely available and routine procedure in cardiovascu-
ar medicine [1,2]. Cardiac device-related endocarditis (CDE) has
merged as a serious complication of electrotherapy in the era of
dvanced medical technology and is a growing problem due to
reater patient longevity, limited electrode life-time, an increas-
ng number of abandoned leads, and subclinical symptoms. The
eported incidence after permanent endocardial cardiac device
mplantation varies in the literature from 0.06% to 7% [3–8].We reviewed our experience with CDE endocarditis to deter-
ine (1) the rate of CDE and its mortality, (2) the clinical situations
n which the diagnosis should be suspected, (3) the relative value of
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echocardiography and blood culture to support the diagnosis, and
(4) its optimal management.
Methods
Patients
All cardiac devices implanted in patients at our institution
between January 1980 and December 2011 were reviewed. Patients
with the diagnosis of CDE were evaluated. Because of the long study
period, the patients were split into two  periods (patients admitted
from January 1980 to December 1999, and patients admitted from
January 2000 to November 2011). Clinical characteristics of these
periods are compared.
Investigations1. Blood cultures on admission (three cultures from each patient
with additional cultures if the temperature was >38.5 ◦C or
<36 ◦C). Cultures at the site of battery implantation were
vier Ltd. All rights reserved.
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Table 1
Clinical characteristics of CDE patients.
Characteristic Value, n = 23
Age (years) 72 median, range 27–80 years
Sex  (M:F) 70:30% (16:7)
Associate diseases
Hypertension 52%
Diabetes mellitus 43%
Coronary artery disease 30%
Indications for device implantation
Atrioventricular block 57%
Sinus node disease 22%
Cardiomypathy ± VT/VF 17%
Vasovagal syncope 4%
Temporary pacemaker inserted 26%
Device type
PPM 83% (4 VVI, 15 DDD)
ICD 17%
Average procedure time 55 min
Last procedure prior to CDE
De novo implantation 35% (8)
Pocket revision 56% (13)
Generator exchange 9% (2)
Time from the last procedure 20 months (range 23 days to
6.1 years)
Antibiotic prophylaxis at implantation 100% (23)
CDE, cardiac device-related endocarditis; DDD, two chamber; ICD, intra-cardiac76 D. Osmonov et al. / Journal 
performed when appropriate (wounds, local infection, or device
exteriorization). All cultures were performed before antibiotic
therapy except in the case of patients referred from other insti-
tutions who were already receiving antibiotic therapy for fever
of unknown origin.
. Cultures of the leads and of the devices were done after removal.
In all of patients, the removal was performed without interrup-
tion of the antimicrobial therapy.
. Transthoracic echocardiography (TTE) could be performed
whenever possible. Serial echocardiograms for suspicion of an
infected lead were performed in some patients. Transesophageal
echocardiography (TEE) was done for patients, who could toler-
ate the procedure, with suspicion of lead vegetation on TTE or
high clinical suspicion of CDE.
iagnostic criteria of endocarditis
A diagnosis of infective endocarditis is established by the pres-
nce of clinical signs and symptoms, and/or positive blood cultures,
nd the visualization of vegetation on the pacemaker electrode and
ricuspid valve in echocardiography [9].  Because pacemakers and
ransvenous intracardiac deﬁbrillator (ICD) are structurally simi-
ar, patients with infection involving either of these devices were
ncluded in the present report.
Early onset endocarditis was deﬁned as an infection occurring
6 months after the last procedure, and late-onset endocarditis was
eﬁned as an infection >6 months later from the last procedure.
n infected anatomic site was considered to be the source of bac-
eremia if consistent focal manifestations preceded the diagnosis of
acteremia and the microorganisms were recovered from adequate
ite specimens.
ntimicrobial therapy
All patients received antibiotic treatment, starting just after
btaining three samples of blood cultures, for an average of 6
eeks (at least 28 days). This therapy was adapted to the germ
ound at the blood culture. If blood cultures were negative, empiri-
al antistaphylococcal therapy was given (usually vancomycin and
mikacin). Antibiotic therapy was continued intravenously for a
inimum of 4 weeks for whom the lead was in place or 3 weeks
fter lead extraction; the antibiotic was adapted to the germ found
t lead culture. Antibiotic therapy was discontinued after infectious
isease specialist consultation to verify the absence of recurrent
ymptoms and normalization of the systemic parameters of inﬂam-
ation.
ead removal
Indications for complete pacemaker system removal were: local
nfectious symptoms and signs in the pacemaker pocket, positive
lood cultures, and the presence of endocardial involvement on
chocardiography. Lead extraction was not performed to those who
enied the procedure. Leads with implant time <2 years and vege-
ation size of <10 mm on TEE were initially tried with percutaneous
imple traction. If it was unsuccessful or implant time was  >2 years
r vegetation size was >10 mm on TEE an extraction with cardiopul-
onary bypass was performed. Partial removal of the lead was
eﬁned as unsuccessful extraction.
ead reimplantationAll lead extracted patients encouraged to have de novo endo-
ardial (after the elimination of bacteremia) or epicardial lead
lacement.deﬁbrillator; PPM, permanent pacemaker; VT/VF, ventricular tachycardia or ﬁbril-
lation; VVI, single chamber.
Follow-up
Infection was considered ‘cured’ if no recurrence was detected
within the follow-up period (median time 49 months). An outpa-
tient clinic was  used for follow-up one month after the discharge.
Further follow-up was  obtained by telephone contact with the
patients.
Statistical analysis
Categorical measures were summarized by using counts and
percentages; continuous variables were summarized by using
either means with standard deviations or medians with an
inter-quartile range, depending on data skew. Univariate com-
parison between continuous variables was  performed with the
Mann–Whitney U test, and for categorical data, comparison was
performed with the Chi-square test. A p-value <0.05 was consid-
ered statistically signiﬁcant. All statistical studies were carried out
using NCSS (Number Cruncher Statistical System) 2007 and PASS
2008 Statistical Software Program (Kaysville, UT,  USA).
Results
Epidemiology
CDE rate
During the study period 5287 operations were performed in our
institution. There were 20 cases (71% male, median age 71 years) of
CDE, yielding a CDE rate of 0.38%. A further 3 cases related to proce-
dures at other hospitals were not included in the calculation of CDE
rate but were used in the overall analysis. A total of 23 cases of CDE
were identiﬁed (16 male, median age 72 years). Clinical character-
istics of all CDE patients are given in Table 1, and characteristics of
the ﬁrst and last periods are compared in Table 2.Operation and device characteristics
Fifteen patients received DDD pacemaker, 4 VVI, and 4 ICD. The
median implant time was  4 years (range 2 months to 27 years).
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Table  2
Characteristics of patients with CDE between the years 1980–1999 and 2000–2011.
Characteristics 1980–1999 2000–2011
Total procedures performed (n) 1920 3367
Cases of CDE (n) 7 16
Microbiologic cultures (n)
S. aureus 6 4
Coag (−) S. – 2
S.  capitis – 1
Brucella – 1
Pseudomonas aeruginosa – 2
Enterococcus fecalis 1 –
Coag (−) S. + G (−) Bacilli – 1
Management (n)
Antibiotic therapy (%) 100% 100%
Cefazol – 5
Vanco 2 2
Ciproﬂoxacin – 3
Combination therapy
Vanco + gentamicin 4 4
Vanco + amikacin 1 2
Duration of antibiotics 8 weeks 6 weeks
Lead extraction (%) 57% 81%
Percutaneously 1 6
Surgically 3 7
Outcome (n)
ARF due to Vanco – 1
SPE – 1
Splenic abscess – 1
Death due to CDE 1 3
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Table 3
Clinical symptoms and echocardiography/microbiologic results.
Clinical characteristic Percent (total n = 23)
Symptoms
Fever 52% (12)
Local device pocket infection 56% (13)
Dyspnea 4.3% (1)
Vegetation on echocardiography 61% (14)
Transthoracic 38% of 21 cases
Transesophageal 81% of 16 cases
Microbiologic cultures
Blood culture-positive 78% (18)
of fever was  excluded); 13.2 days in cases with pocket infection;
and 13 days in the case with congestive heart failure.
Table 4
Characteristics of patients in early and late onset endocarditis groups.
Characteristics Early-onset
endocarditis (n = 6)
Late-onset endocarditis
(n = 17)RF, acute renal failure; CDE, cardiac device-related endocarditis; Coag, coagulase;
,  Gram; S., Staphylococcus; SPE, septic pulmonary embolism; Vanco, vancomycin.
In our institution we routinely administer intravenous cefazolin
t the time of the device implantation and continue for 36–48 h. The
verage duration of procedure is 50 min  and the patient’s hospital
tay is 4 days (36–48 h after the procedure).
The average number of operations that is performed prior to
resentation was 2.3; 8 cases (35%) followed de novo implantations
p > 0.05) (Fig. 1).
The median time from the last device manipulation to the diag-
osis was 20 months (range 23 days to 6.1 years) and 35% presented
ithin the ﬁrst 12 months; only 6 patients presented within 6
onths.linical presentation and ﬁndings
Thirteen cases (56%) presented with pocket infection symptoms
e.g. erosion, drainage, lead or device extrusion), 12 (52%) with fever
ig. 1. Number of operations performed prior to presentation in patients with car-
iac  device-related endocarditis (CDE).Generator site swab positive 40% of 10 cases
Lead site swab positive 50% of 8 cases
(>38 ◦C), and one with congestive heart failure; 3 cases presented
with both fever and pocket infection symptoms (Table 3). Sixteen
cases (70%) were found to have a device pocket infection (three of
them were unaware of infection).
Six patients presented within 6 months after the last procedure
– early-onset endocarditis group; 74% after >6 months – late-onset
endocarditis group. In the early-onset endocarditis group the aver-
age admission time since the onset of symptoms was 8 days, but it
was 23.8 days in late-onset endocarditis group (p = 0.024). One case
in late-onset endocarditis group was admitted 180 days later after
the onset of symptoms. During this period he was  continuously
placed on different antibiotics, and when fever persisted despite
the therapy he was admitted to our institution. When this patient
was excluded from the late-onset endocarditis group the admis-
sion time was  still long in the late-onset endocarditis group (14.7
days, p = 0.032). Clinical characteristics of both early- and late-onset
endocarditis groups are given in Table 4.
The time between the onset of symptoms and deﬁnite diagnosis
of CDE was similar based on the type of symptom; 13.3 days in cases
with fever (patient who was admitted 180 days later after the onsetDevice pocket infection 100% (6) 59% (10)
Microbiologic cultures 100% (6) 70% (12)
S. aureus 50% (3) 58% (7)
Coag (−) S. 33% (2) –
S. capitis – 8% (1)
Brucella – 8% (1)
Pseudomonas aeruginosa 17% (1) 8% (1)
Enterococcus fecalis – 8% (1)
Coag (−) S. + G (−) Bacilli – 8% (1)
Management
Antibiotic treatment 100% 100%
Combination therapy 50% (3) 47% (8)
Duration of antibiotics 4–24 weeks (average
8.3 weeks)
4–8 weeks (average 5.4
weeks)
Lead extraction 67% (4) 76% (13)
Percutaneously 1 6
Surgically 3 7
Outcome
Complications 17% (1) 35% (6)
ARF due to vancomycin 1 –
Death due to CDE – 4
SPE – 1
Splenic abscess – 1
ARF, acute renal failure; CDE, cardiac device-related endocarditis; Coag, coagulase;
early-onset endocarditis: presentation within six months after the last procedure;
G,  Gram; late-onset endocarditis: presentation later than six months after the last
procedure; S., Staphylococcus; SPE, septic pulmonary embolism.
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Fig. 2. A pathogen was  isolated from blood culture in 18 cases (78%). In one patient
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ywo organisms were identiﬁed (Coag (−) Staph and Gr (−) Bacillus). S. aureus,  Staphy-
ococcus aureus; Staph, staphylococcus; Coag (−), coagulase negative; Gr (−), Gram
egative; P. aeruginosa, Pseudomonas aeruginosa.
icrobiology
A pathogen was isolated from blood culture in 18 cases (78%):
6% Staphylococcus aureus (2 cases methicillin-resistant, MRSA),
2% coagulase-negative Staphylococci (1 case methicillin resistant
taphylococcus epidermidis, MRSE), 28% other (Fig. 2). In 6 of 18 cases
33%), the pathogen was cultured either from blood and samples
aken from the generator site or extracted lead; in 4 of 6 cases,
he germ cultured from extracted lead was different than the germ
ultured from blood. In these 4 cases antimicrobial therapy was
dapted according to the lead-derived pathogen, and it was  suc-
essful in eradicating the causative organism of CDE after 2 weeks
f therapy.
In one case, brucella was  cultured either from blood and sample
aken from extracted leads; vegetation observed on TEE; leads were
xtracted percutaneously by simple traction and 6 weeks of antimi-
robial therapy was scheduled. The patient had a second attack of
ight-sided endocarditis three years after the CDE; S. aureus was
he causative agent.
In 2 cases, Pseudomonas aeruginosa was the causative agent; cul-
ured from blood; vegetation observed on TEE. One of these patients
nderwent a surgical lead removal. The second one underwent per-
utaneous removal of the leads and new leads were reimplanted
rom an opposite site.
chocardiography
TTE and TEE were performed in 91% and 70% of cases, respec-
ively; 9% had neither performed. Of the 16 cases (70%) that
nderwent both, the TEE offered additional or diagnostic infor-
ation in 7 cases (44%). Lead vegetations were determined at
chocardiography in 14 cases overall; 7 TTE and 13 TEE studies
emonstrated deﬁnite lead vegetations.
anagement
All cases received intravenous antibiotics. Device removal was
erformed in 19 cases (82.6%) – the complete system (i.e. genera-
or and all associated leads) was removed in 17 cases (32 leads)
nd the generator alone in 2. Leads could not be removed per-
utaneously in two patients and they denied surgical extraction
rocedure. The system extraction was performed percutaneously
n 7 cases (13 leads) and in 10 cases (59% of extraction operations)
eads were removed via sternotomy (19 leads) by cardiothoracic
urgeons due to the vegetation size, an implant time that was >2
ears, or unsuccessful removal by percutaneous approach. In 3 ofiology 61 (2013) 175–180
10 patients, for whom surgery was  applied, the lead tips could not
be removed due to extensive ﬁbrosis. New devices were inserted in
56.5% of cases after a median of 17 days; 5 epicardial and 8 endocar-
dial. Thirty one percent of complete hardware explanted patients
were not implanted a new device; one ICD; two  DDD; and one VVI
pacemakers.
Six cases who did not have lead(s) extracted were placed on
long-term (>6 weeks) suppressive antibiotics and all were eventu-
ally considered cured after medical treatment. Two cases (10.5%
of patients who  survived) had recurrent endocarditis; both had
evidence of vegetation on echocardiography and underwent suc-
cessful complete system removal at the time of their presentation
with a CDE. A germ (cultured form blood) speciﬁc antimicrobial
therapy resolved symptoms and normalized systemic parameters
of inﬂammation, after 4 weeks of therapy, in these two  patients.
Major complications
Characteristics of patients who  suffered a major complication
are given in Table 5. Four patients died due to the CDE, represent-
ing a mortality rate of 17.4%. All deaths occurred in the late-onset
endocarditis group (p > 0.05).
One case who  suffered splenic abscess, which was thought
attributable to the paradoxical embolism of the vegetation from
a patent foramen ovale, underwent a splenectomy.
A case who  suffered septic pulmonary embolism had an evi-
dence of vegetation (<10 mm)  on the lead both on TTE and TEE.
One patient experienced an acute renal failure secondary to the
vancomycin therapy which was improved with dose reduction (the
only complication in the early-onset endocarditis group). Overall,
7 patients with CDE experienced a major complication; 6 patients
have had a major complication secondary to the CDE giving a rate
of 26% (all in the late-onset endocarditis group, p > 0.05).
Discussion
Major ﬁndings of this report are (1) the rate of CDE is 0.38%,
(2) TEE could detect the vegetation in 81% of cases of CDE, (3)
a pathogen could be cultured from blood in 78% of cases with
CDE, (4) CDE is a serious disease which has major complication
and mortality rates of 26% and 17.4%, respectively, (5) patients in
the early-onset endocarditis group were admitted earlier than the
late-onset endocarditis group, and (6) appropriate antimicrobial
therapy in association with complete hardware removal should
always be considered in the management of CDE [10].
Clinical presentation
Only 6 patients (26%) presented within 6 months after the last
procedure and they were admitted shortly after the onset of symp-
toms. In the early post procedure admissions, the short time elapsed
between cardiac device implantation and the occurrence of infec-
tion facilitated the diagnosis [9].  Early diagnosis and initiation of
appropriate therapy is suggested to be effective in eradicating an
infection, and might preserve a patient from the occurrence of a
major complication.
In the late-onset endocarditis group, the delay between the
onset of symptoms and the diagnosis illustrates the difﬁculty in
diagnosing CDE, as has been recognized previously [9,11,12,4].  In
our population, the delay in diagnosis was often related to the fact
that CDE was  not considered in the differential diagnosis. Hence,
one of the patients was admitted as long as 180 days later after
the onset of symptoms. S. aureus was cultured from blood, and
six weeks of vancomycin and amikacin therapy in association with
removal (by percutaneous simple traction) of atrial and ventricular
leads cured an infection in this patient.
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Table  5
Characteristics of patients with major complication.
Case/age Device Presentation Pathogen Vegetation on
TTE/TEE
Initial hardware removal Reinserted
new device
Outcome
1/72y DDD PI S. aureus No/Yes Not performed – ARF due to vancomycin
2/77y VVI Fever G (−) Bacilli No/Yes Not performed – Splenic abscess-splenectomy
3/78y  ICD PI Not identiﬁed No/Yes Not performed – Died in hospital due to SPE
4/37y  ICD PI S. aureus No/– Not performed – Died in hospital due to sepsis
5/78y  VVI Fever S. aureus No/– Partial# No Died in hospital due to sepsis
6/73y  DDD Fever + PI S. capitis Yes/Yes Complete# No Died in hospital due to MOF
7/61y DDD Fever Not identiﬁed Yes/Yes Complete* No SPE
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(RF, acute renal failure; G (−), Gram negative; leads removed surgically# or percu
mbolism; S., Staphylococcus; TTE, transthoracic echocardiography; TEE, transesoph
In agreement with the studies recently published by Sohail et al.
nd Baman et al. [10,13], a majority of patients with CDE in our
ohort presented with evidence of infection limited only to the site
f the generator. Most of our population were erroneously consid-
red to have a symptom secondary to the local infection and taken
o the operation room, without further evaluation, for the revision
f the pocket. This misdiagnosis or unawareness was  made by car-
iologists who  are thought to be the most authorized doctors in
etecting a CDE. It must be reemphasized that such a benign clin-
cal presentation can lead to an outcome of substantial morbidity
nd mortality. The second most frequent symptom is a fever (52% of
ur population), and patients with fever are generally admitted to
he local hospitals. The other physician group including therapists
most patients with fever visited a therapist) did not consider a CDE,
s well as cardiologists, in the differential diagnosis. It is therefore
aluable to keep in mind a differential diagnosis of CDE in patients
ith septic or local infection signs within the pacemaker site, and
ulmonary symptoms for whom a cardiac device was  implanted.
oreover, further investigations including echocardiography and
lood culture should be considered [10].
icrobiology
Blood cultures play an important role in the diagnostic process
n cases of suspected infective endocarditis. According to the lit-
rature, the most frequently encountered pathogens isolated from
lood, wound, and electrode cultures of patients with pacemaker-
ssociated sepsis include coagulase positive and coagulase negative
taphylococci (80%) and this is consistent with the blood culture
ndings of most of our cohort [3,4,6,14–17]. Microorganisms had
een cultured in all of seven patients in the ﬁrst half period, whereas
nly 11 of 16 of patients (69%) had positive cultures in the second
alf period. This difference might be related to the ease of access
nd the extensive use of antibiotics in the 21st century.
Brucella and P. aeruginosa were cultured in three cases (13% of
ur cohort). These are rare but potentially dangerous pathogens
f CDE, and they should be kept in mind. All three patients with
hese pathogens had evidence of vegetation on echocardiography
nd the complete device system was removed. One case with bru-
ella and one with P. aeruginosa experienced a second attack of
ndocarditis (S. aureus was isolated) after complete eradication of
nitial pathogens. In patients with negative blood cultures, longer
ncubation periods and Wright agglutination or Rose Bengal tests
ight be helpful in identifying brucella.
chocardiography
Overall rate of echocardiography was 91%; 70% TEE. Previous
tudies of permanent pacemaker/ICD lead endocarditis have con-
rmed the superiority of TEE over TTE and this was demonstrated
n the present study; additional diagnostic value in 6 of 13 patients
44%) [18,19]. Studies of generator site infections suggest a highsly*; MOF, multi organ failure; PI, device pocket infection; SPE, septic pulmonary
 echocardiography.
rate of lead colonization or infection by the same organism iso-
lated from the generator site [20] and some centers employ routine
echocardiography to exclude lead endocarditis in cases of genera-
tor site infection, as the detection of vegetation has a major impact
upon the therapeutic strategy; unfortunately the negative predic-
tive value of TEE has been reported to be as low as 30% [10]. The
incidence of combined generator/lead infection is often underesti-
mated – it was determined that no less than 70% of our population
had evidence of both generator and lead infections. We  suggest that
TEE may  have an important diagnostic value in patients with pocket
infection. Moreover, it should be considered routinely in those with
multiple attacks of pocket infection.
Management
Eighty-two percent of patients undergoing device extraction
had successful percutaneous or surgical removal of the device hard-
ware in our study. After complete hardware extraction and control
of infection, the need for the replacement of device must be care-
fully assessed. Because, according to the current cardiac device
guidelines some patients might have been implanted a cardiac
device with Class II b indication [21], and we thought that the risk
of CDE outweigh the beneﬁt of the device in these patients. Of note,
in published series, up to 50% of pacemaker patients do not require
further implantation after device removal [22]. In our series, 31% of
complete hardware (one ICD, two  DDD, and one VVI pacemakers)
explanted patients were not implanted a new device.
Re-implantation of the device should be at a new site or epicar-
dially. Timing of the re-implantation is still debated. Some authors
recommend delaying re-implantation up to 6 weeks, although the
consensus currently suggests that re-implantation can take place
when patients are no longer bacteremic [10]. The duration of antibi-
otic therapy depends largely on the infective organism and the
clinical presentation, and it has varied widely in the published lit-
erature [10,16,17,21].  Some series have recommended 6 weeks of
therapy after device removal. However, with most cases of device-
related endocarditis limited to the right heart, some authors have
suggested 4 weeks of therapy should be adequate [10,22].  In our
study, the median duration of antibiotics in total was 42 days.
Outcomes
A CDE-related mortality rate of 17.4% was  demonstrated among
this small cohort, comparing favorably to other studies of this
condition [13,23]. Although statistically insigniﬁcant, the late-
onset endocarditis seems to be more morbid and mortal than the
early-onset endocarditis. We  suggest that the main reason of this
tendency in the late-onset endocarditis is an elapsed time spent
until the diagnosis of the condition. This rare but lethal condition
should be suspected in all patients with various infective symp-
toms, who have a cardiac device implanted, especially in those with
long post procedure time.
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imitations
The present study is a retrospective analysis, and thus bears
he inherent limitations of such studies. The incidence and num-
er of cases may  be underestimated due to referral bias, as our
nstitution is a tertiary referral unit and perhaps some less severe
ases were managed locally, without reaching our attention. Data
rom TEE were available in only 70% of patients where the study
as determined to be clinically indicated. Although this may  have
nderestimated the true frequency of some echocardiographic
ndings (such as vegetations), we had surface echocardiograms
vailable in the great majority of patients. The rate of morbidity
nd mortality of a CDE may  be overestimated in our cohort. The
ovel techniques of the lead extraction were not applied to our
atients [24,25],  because most of them were determined to have a
DE before the existence of these techniques which might inﬂuence
he rate of morbidity and mortality for this condition.
onclusion
CDE remains a rare but potentially fatally complication of device
mplantation. The diagnosis of CDE should be suspected in the
resence of pocket infection and/or fever after cardiac device inser-
ion. TEE and blood culture are the most valuable diagnostic tools.
anagement should consist of complete hardware extraction and
ong-term administration of broad-spectrum antibiotics that cover
he germ cultured from blood or samples from leads that were
xtracted.
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